A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

NCT04965090 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non Small Cell Lung Cancer
Recurrent Non Small Cell Lung Cancer

Interventions

DRUG: Amivantamab
DRUG: Lazertinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]